Skip to main content
. 2015 May 27;17(4):331–337. doi: 10.1007/s40272-015-0136-2

Table 2.

Number of children with GI-relateda diagnoses among chronic users of metoclopramide, Truven Health MarketScan® Commercial Claims and Encounters database

Diagnosis Total cohort Non-users Usersb Chronic (35 days)c Chronic (130 days)
Age < 1 year
 Total cohort size 192,560 (100 %) 190,597 (100 %) 1963 (100 %) 900 (100 %) 226 (100 %)
 GERD 22,002 (11.43 %) 20,478 (10.74 %) 1524 (77.64 %) 729 (81.00 %) 190 (84.07 %)
 GI diagnoses 16,487 (8.56 %) 15,788 (8.28 %) 699 (35.61 %) 319 (35.44 %) 80 (35.4 %)
 Neuro-GI disorders 34,921 (18.14 %) 34,242 (17.97 %) 679 (34.59 %) 340 (37.78 %) 99 (43.81 %)
Age 1 to <2 years
 Total cohort size 220,597 (100 %) 219,223 (100 %) 1374 (100 %) 593 (100 %) 178 (100 %)
 GERD 9393 (4.26 %) 8545 (3.90 %) 848 (61.72 %) 466 (78.58 %) 142 (79.78 %)
 GI diagnoses 22,539 (10.22 %) 21,995 (10.03 %) 544 (39.59 %) 237 (39.97 %) 74 (41.57 %)
 Neuro-GI disorders 14,504 (6.57 %) 14,106 (6.43 %) 398 (28.97 %) 228 (38.45 %) 81 (45.51 %)
Age 2–6 years
 Total cohort size 689,070 (100 %) 688,227 (100 %) 843 (100 %) 248 (100 %) 108 (100 %)
 GERD 6035 (0.88 %) 5745 (0.83 %) 290 (34.4 %) 162 (65.32 %) 76 (70.37 %)
 GI diagnoses 55,668 (8.08 %) 55,283 (8.03 %) 385 (45.67 %) 140 (56.45 %) 63 (58.33 %)
 Neuro-GI disorders 17,967 (2.61 %) 17,780 (2.58 %) 187 (22.18 %) 123 (49.6 %) 69 (63.89 %)
Age 7–17 years
 Total cohort size 1,974,370 (100 %) 1,971,422 (100 %) 2948 (100 %) 554 (100 %) 156 (100 %)
 GERD 17,165 (0.87 %) 16,420 (0.83 %) 745 (25.27 %) 287 (51.81 %) 82 (52.56 %)
 GI diagnoses 76,965 (3.9 %) 75,707 (3.84 %) 1258 (42.67 %) 305 (55.05 %) 82 (52.56 %)
 Neuro-GI disorders 39,536 (2.00 %) 39,119 (1.98 %) 417 (14.15 %) 158 (28.52 %) 64 (41.03 %)

GERD symptomatic gastroesophageal reflux, GI gastrointestinal, Neuro-GI neurogastroenterology

aNote that patients could be assigned to multiple diagnostic groups

bThe last three columns are nested. Users includes all chronic users

cChronic users with 130 days’ supply were included in with the chronic users with at least 35 days’ supply